tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Chimeric Therapeutics Advances Cancer Treatment with Key Milestones and Funding

Story Highlights
Chimeric Therapeutics Advances Cancer Treatment with Key Milestones and Funding

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Chimeric Therapeutics Ltd. ( (AU:CHM) ) just unveiled an announcement.

Chimeric Therapeutics has made significant progress in its CHM CDH17 program, advancing to dose level 2 in its Phase 1/2 study for gastroenteropancreatic neuroendocrine tumors. The company received FDA Fast Track Designation and activated a fourth US clinical site, demonstrating its commitment to accelerating clinical pipelines. The ADVENT-AML Phase 1B trial also reported promising early results, and the company successfully raised $16.6 million to support its initiatives. These developments position Chimeric as a key player in the cell therapy industry, potentially impacting stakeholders positively by advancing cancer treatment options.

More about Chimeric Therapeutics Ltd.

Chimeric Therapeutics Limited is an Australian company specializing in cell therapy. It focuses on developing advanced treatments for cancer, particularly through its innovative CAR-T cell therapy programs.

Technical Sentiment Signal: Sell

Current Market Cap: A$9.75M

See more data about CHM stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1